Minglei Teng

Minglei Teng

Auto-generated profile, based on publicly available information

Minglei Teng

State Key Laboratory of Infectious Disease Vaccine Development, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, Fujian Engineering Research Center of Molecular Theranostic Technology, Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2022 in Chinese Chemical Letters
Verified
Journal Article
Closed access
HCHu Chen
Hu Chen
MTMinglei Teng
Minglei Teng
HZHongrui Zhang
Hongrui Zhang
XLXiaoliu Liang
Xiaoliu Liang
Hongwei ChengHongwei Cheng
Hongwei Cheng
Gang LiuGang Liu
Gang Liu

21 February 2025 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
HCHu Chen
Hu Chen
YXYongfu Xiong
Yongfu Xiong
MTMinglei Teng
Minglei Teng
YLYesen Li
Yesen Li
DZDeliang Zhang
Deliang Zhang
Gang LiuGang Liu
Gang Liu
Transarterial radioembolization (TARE) is a widely utilized therapeutic approach for hepatocellular carcinoma (HCC), however, the clinical implementation is constrained by the stringent preparation conditions of radioembolization agents. Herein, we incorporated the superstable homogeneous iodinated formulation technology (SHIFT), simultaneously utilizing an enhanced solvent form in a carbon dioxide supercritical fluid environment, to encapsulate radionuclides (such as 131I,177Lu, or 18F) with lipiodol for the preparation of radiolipiodol. The resulting radiolipiodol exhibited exceptional stability and ultra-high labeling efficiency (≥99%) and displayed notable intratumoral radionuclide retention and in vivo stability more than 2 weeks following locoregional injection in subcutaneous tumors in mice and orthotopic liver tumors in rats and rabbits. Given these encouraging findings, 18F was authorized as a radiotracer in radiolipiodol for clinical trials in HCC patients, and showed a favorable tumor accumulation, with a tumor-to-liver uptake ratio of ≥50 and minimal radionuclide leakage, confirming the feasibility of SHIFT for TARE applications. In the context of transforming from preclinical to clinical screening, the preparation of radiolipiodol by SHIFT represents an innovative physical strategy for radionuclide encapsulation. Hence, this work offers a reliable and efficient approach for TARE in HCC, showing considerable promise for clinical application (ChiCTR2400087731).

1 December 2019
Verified
Conference Paper
Closed access
XFXianbao Fan
Xianbao Fan
MTMinglei Teng
Minglei Teng
DFDan Fan
Dan Fan
RWRui Wang Wang
Rui Wang Wang
BSBohao Sun
Bohao Sun
Nowadays, the spectrum analyzer is large in size, which is not convenient for technicians to carry, and the price is expensive. To solve these problems, this paper designs a micro-spectrum analyzer based on FPGA+AD9361 architecture, which supports channel bandwidth from 200KHz to 56MHz,and realizes spectrum detection in the range of 70MHz~6GHz [1]. The micro-spectrum analyzer adopts the AD9361 RF integrated chip as the RF front-end processing module, adopts zero-IF design structure, and has the characteristics of small size, high performance, low power consumption, easy to use, and easy to expand functionality. It can be widely used in mobile spectrum detection and other occasions.